Home  |  Contact

UniProtKB/Swiss-Prot Q9NRR6: Variant p.Arg621Gln

Phosphatidylinositol polyphosphate 5-phosphatase type IV
Gene: INPP5E
Variant information

Variant position:  621
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Arginine (R) to Glutamine (Q) at position 621 (R621Q, p.Arg621Gln).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and polar (Q)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Joubert syndrome 1 (JBTS1) [MIM:213300]: A disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy and renal disease. {ECO:0000269|PubMed:19668216, ECO:0000269|PubMed:23034536, ECO:0000269|PubMed:23386033, ECO:0000269|PubMed:29052317}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In JBTS1.
Any additional useful information about the variant.

Sequence information

Variant position:  621
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  644
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.





Drosophila                    AIPLAAGLFSRDIYLEGMRRRLNN--------QYSGASAVC

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 1 – 641 Phosphatidylinositol polyphosphate 5-phosphatase type IV
Modified residue 641 – 641 Cysteine methyl ester
Lipidation 641 – 641 S-farnesyl cysteine
Mutagenesis 641 – 641 C -> A. Abolishes farnesylation-dependent interaction with PDE6D.
Helix 611 – 623

Literature citations

Phenotypic spectrum and prevalence of INPP5E mutations in Joubert syndrome and related disorders.
Travaglini L.; Brancati F.; Silhavy J.; Iannicelli M.; Nickerson E.; Elkhartoufi N.; Scott E.; Spencer E.; Gabriel S.; Thomas S.; Ben-Zeev B.; Bertini E.; Boltshauser E.; Chaouch M.; Cilio M.R.; de Jong M.M.; Kayserili H.; Ogur G.; Poretti A.; Signorini S.; Uziel G.; Zaki M.S.; Johnson C.; Attie-Bitach T.; Gleeson J.G.; Valente E.M.;
Eur. J. Hum. Genet. 21:1074-1078(2013)
Cited for: VARIANTS JBTS1 ARG-286; MET-303; SER-345; ASN-426; GLN-435; ARG-474; ASP-534; HIS-563; CYS-585; GLN-621 AND ARG-641;

The diagnostic utility of exome sequencing in Joubert syndrome and related disorders.
Tsurusaki Y.; Kobayashi Y.; Hisano M.; Ito S.; Doi H.; Nakashima M.; Saitsu H.; Matsumoto N.; Miyake N.;
J. Hum. Genet. 58:113-115(2013)

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.